In addition, when pathological examination of the tissue after surgery indeed shows high expression of CXCR4, the residual (or possibly recurrent) tumor might be receptive to treatment with [177Lu]Lu-Pentixather. This evidence concerns the gene CXCR4 and neoplasm.